Myriad Genetics, Inc. (Nasdaq: MYGN) to Ring The Nasdaq Stock Market Opening Bell
September 21 2015 - 8:46PM
What:
Myriad Genetics, Inc. (Nasdaq:MYGN), a leader in the
personalized medicine industry with innovative, high-quality
molecular diagnostics, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Mark C. Capone, President and Chief
Executive Officer will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Monday, September 14, 2015 – 9:15 a.m. to 9:30 a.m.
ET
Myriad Genetics, Inc. Media Contact:Ron
Rogers(801) 584-3065rrogers@myriad.com
Nasdaq MarketSite:Angela Tu(646)
225-0316Angela.Tu@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page
at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Opening Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Myriad Genetics, Inc.
(Nasdaq:MYGN):
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where
molecular diagnostics can significantly improve patient care and
lower healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer testing market, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,600 listed companies
with a market value of approximately $9.6 trillion and more than
10,000 corporate clients. To learn more, visit: nasdaq.com/ambition
or business.nasdaq.com.
-NDAQA-
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024